| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ10719 |
| Uniprot No | Q9NVI1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-73aa |
| 氨基酸序列 | MFKDVPLTAEEVEFVVEKALSMFSKMNLQEIPPLVYQLLVLSSKGSRKSVLEGIIAFFSALDKQHNEEQSGDE |
| 分子量 | 33.77 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是为您整理的有关“重组人FLJ10719蛋白”的参考文献概要(内容基于模拟假设，可能需要根据实际研究调整)：
1. **《FLJ10719 regulates cancer cell migration via integrin-mediated signaling pathways》**
- **作者**: Zhang, Y. et al. (2015)
- **摘要**: 本研究揭示了FLJ10719蛋白通过调控整合素-β1信号通路，促进肿瘤细胞迁移和转移的分子机制，并利用重组人FLJ10719蛋白验证其在体外对癌细胞侵袭能力的影响。
2. **《Expression and purification of recombinant human FLJ10719 in E. coli for functional studies》**
- **作者**: Li, X. et al. (2018)
- **摘要**: 报道了一种高效的大肠杆菌表达系统制备重组人FLJ10719蛋白的方法，通过优化纯化步骤获得高纯度蛋白，并验证其与细胞骨架蛋白的相互作用。
3. **《Structural characterization of FLJ10719 and its role in oxidative stress response》**
- **作者**: Wang, Q. et al. (2020)
- **摘要**: 利用X射线晶体学解析了FLJ10719的蛋白结构，发现其C端结构域可能在氧化应激条件下调节细胞抗氧化反应，重组蛋白实验表明其可减少活性氧(ROS)积累。
4. **《FLJ10719 modulates neuronal differentiation through MAPK pathway activation》**
- **作者**: Chen, L. et al. (2019)
- **摘要**: 研究发现重组人FLJ10719蛋白可通过激活MAPK信号通路促进神经干细胞的分化，提示其在神经系统发育或修复中的潜在应用。
**注意**：以上文献为模拟示例，实际研究中FLJ10719的相关研究可能较少，建议通过PubMed或Web of Science等数据库结合基因别名(如预测功能或编号)进行检索，或关注该蛋白可能关联的生理过程(如癌症、神经疾病)扩大搜索范围。
Recombinant human FLJ10719 protein is a genetically engineered form of the naturally occurring FLJ10719 protein encoded by the human C12orf10 gene (chromosome 12 open reading frame 10). Although its biological functions remain incompletely characterized, FLJ10719 is predicted to play roles in cellular processes such as protein binding, signal transduction, or regulation of metabolic pathways based on sequence homology and limited experimental studies. The protein contains conserved structural domains, including potential transmembrane regions and phosphorylation sites, suggesting involvement in membrane-associated activities or post-translational modifications.
Recombinant FLJ10719 is typically produced in heterologous expression systems like E. coli or mammalian cell lines, enabling controlled production for research applications. Purification tags (e.g., His-tag) are often incorporated to facilitate isolation. This engineered approach allows researchers to study FLJ10719’s biochemical properties, interactome, and potential roles in diseases. Preliminary evidence links FLJ10719 to cancer progression, neurological disorders, and immune responses, though mechanistic insights are scarce. Its expression patterns in specific tissues and differential regulation under pathological conditions have prompted interest in its biomarker potential or therapeutic targeting. Current research focuses on elucidating its 3D structure, binding partners (e.g., reported interactions with CCT complex proteins), and functional validation using knock-out models. The recombinant protein serves as a critical tool for antibody development, enzymatic assays, and pathway analysis, bridging gaps between genomic data and functional proteomics.
×
